Physician profile
David Shin
NPI 1558320994
$4,399.15
in general payments reported to CMS, 2019-2025
14 companies · $386 in 2025
The $386 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $406 · 2020: $1,507 · 2022: $1,192 · 2023: $321 · 2024: $587 · 2025: $386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,193 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,193.24 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,124.80 | 2019-2024 | Ams 700 |
| Intuitive Surgical, INC. | $1,051.05 | 2022 | |
| Antares Pharma, INC. | $294.63 | 2019-2023 | Xyosted, Tlando |
| Tolmar, INC. | $189.91 | 2024 | |
| Sun Pharmaceutical Industries INC. | $161.32 | 2024-2025 | |
| Procept Biorobotics Corporation | $149.45 | 2025 | |
| Janssen Biotech, INC. | $129.61 | 2022-2025 | Tremfya, Erleada |
| Kerecis Limited | $106.37 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Urogen Pharma, INC. | $64.40 | 2022-2024 | Jelmyto |
| Pfizer INC. | $61.41 | 2019-2023 | |
| Karl Storz Endoscopy-America | $20.63 | 2019 | |
| Azurity Pharmaceuticals, INC. | $17.72 | 2025 | Azmiro |
| Astellas Pharma US INC | $14.06 | 2022 | |
| C. R. Bard, INC. & Subsidiaries | $13.79 | 2023 | Bard Urinary Drainage Bag |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Shin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.